Systemic Epstein-Barr virus-positive T/natural killer-cell lymphoproliferative disorder: a case report and review of literature.
Systemic Epstein-Barr virus-positive T/natural killer-cell lymphoproliferative disorder (EBV + LPD) has predominantly been observed among pediatric patients as a life-threatening condition. The present study presents a rare case of EBV + LPD in an adult with good outcome. This patient's history is more than 2 years and her condition was stable. She received 6 cycles of chemotherapy cyclophosphamide/doxorubicin/vincristine/prednisolone (CHOP). The evaluation was complete remission. The low levels of EBV-DNA in the peripheral blood may have potential benefit factor for the sensitivity to the chemotherapy and good outcome.
Department of Nephrology, The Second Xiangya Hospital Of Central South University Changsha 410011, Hunan, P.R. China.
Xia
X
Tan
Department of Oncology, The Second Xiangya Hospital Of Central South University Changsha 410011, Hunan, P.R. China.
Xianling
X
Liu
Department of Oncology, The Second Xiangya Hospital Of Central South University Changsha 410011, Hunan, P.R. China.
Chunhong
C
Hu
Department of Nephrology, The Second Xiangya Hospital Of Central South University Changsha 410011, Hunan, P.R. China.
Fuyou
F
Liu
Department of Oncology, The Second Xiangya Hospital Of Central South University Changsha 410011, Hunan, P.R. China.
Fang
F
Wu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000378:metabolism / Q000821:virology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000737:chemistry / Q000821:virology*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000378:metabolism / Q000821:virology*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D013602:T-Lymphocytes, Cytotoxic / Q000737:chemistry / Q000821:virology*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
Epstein-Barr virus; T/natural killer-cell; lymphoproliferative disorder